KETAFREE
ketamine · preservative-free ketamine · NRX-100 Small Molecule Target: NMDA receptor
NRX Pharmaceuticals
Most recent annual filing: 2026-03-23
- NRX-101 Ph3 start2026NRX-101 Ph3 start, 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
D-cycloserine
lurasidone · D-cycloserine/lurasidone · NRX-101 Small Molecule Target: NMDA receptor, NMDA
D-cycloserine
NRX-101D-cycloserine/lurasidone fixed dose combination
NRX-101Technology platforms
NMDA platform
NMDA receptor-targeting platform for central nervous system disorders including suicidal depression, chronic pain, and PTSD
Targets: NMDA
Biotech Distilled coverage (13)
- 2026-08-15 UPDATE: NRx Pharmaceuticals (NRXP) - The ATM Never Went Dormant 🔒 Paid
- 2026-08-08 UPDATE: NRx Pharmaceuticals (NRXP) - The Cap, Not the Compound 🔒 Paid
- 2026-07-22 UPDATE: NRx Pharmaceuticals (NRXP) - DARPA Picks Up the Phone 🔒 Paid
- 2026-06-24 UPDATE: NRx Pharmaceuticals (NRXP) - Kadima Sues, Zeta Goes Live 🔒 Paid
- 2026-06-03 UPDATE: NRx Pharmaceuticals (NRXP) - The Print Lands at $3.50
- 2026-06-02 UPDATE: NRx Pharmaceuticals (NRXP) - The Underwritten Raise Finally Prints
- 2026-05-16 UPDATE: NRx Pharmaceuticals (NRXP) - The ATM Receipts Arrive (And a Swiss Surprise) 🔒 Paid
- 2026-05-08 UPDATE: NRx Pharmaceuticals (NRXP) - The Fertilizer Trial Gets a Green Light 🔒 Paid
- 2026-04-27 UPDATE: NRx Pharmaceuticals (NRXP) - The Hail Mary Becomes a Layup 🔒 Paid
- 2026-03-28 UPDATE: NRX Pharmaceuticals - The 10-K Drops, The ATM Spins, and the Evergreen Grab Passes 🔒 Paid
- 2026-03-21 UPDATE: NRX Pharmaceuticals (NRXP) - The FDA Blinks... 🔒 Paid
- 2026-02-14 UPDATE: NRx Pharmaceuticals (NRXP) — The Proxy Drops (And the Math is Ugly) 🔒 Paid
- 2026-01-13 NRx Pharmaceuticals (NRXP): Scientific Deep Dive for KETAFREE™ 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.